|1.||Reubi, Jean Claude: 28 articles (06/2015 - 05/2003)|
|2.||Krenning, Eric P: 21 articles (02/2016 - 12/2002)|
|3.||Waser, Beatrice: 18 articles (06/2015 - 07/2002)|
|4.||de Jong, Marion: 17 articles (05/2015 - 04/2003)|
|5.||Kwekkeboom, Dik J: 15 articles (02/2016 - 04/2003)|
|6.||Baum, Richard P: 15 articles (07/2015 - 07/2006)|
|7.||Makis, William: 13 articles (01/2016 - 02/2015)|
|8.||McEwan, Alexander J B: 13 articles (01/2016 - 02/2015)|
|9.||McCann, Karey: 13 articles (01/2016 - 02/2015)|
|10.||Bodei, Lisa: 11 articles (12/2015 - 03/2008)|
01/01/2010 - "Cytotoxic analogs were particularly effective on tumors that express the specific peptide receptors and acted more powerfully than the carrier peptide or the cytotoxic compound alone. "
01/01/2013 - "Peptide receptor radionuclide therapy (PRRT) has been shown to be effective against this tumor manifestation. "
12/01/2002 - "Peptide receptor radionuclide therapy with (111)In-DTPA(0)-octreotide is effective in SS-R-positive tumors. "
12/14/2009 - "We report on an initially inoperable malignant pancreatic endocrine tumor in a 33-year-old woman, who received neoadjuvant peptide receptor radionuclide therapy (PRRT) as first-line treatment. "
01/01/2005 - "Peptide receptor radionuclide therapy (PRRT) holds great promise for the future regarding the treatment of various cancers. "
|2.||Neuroendocrine Tumors (Neuroendocrine Tumor)
08/01/2011 - "Peptide receptor radionuclide therapy (PRRT) is an efficient treatment for gastroenteropancreatic neuroendocrine tumors (GEP NETs), with outstanding overall response rates and survival. "
11/01/2012 - "Peptide receptor radionuclide therapy (PRRT) with (177)Lu-DOTATATE is an efficient new treatment option in patients with neuroendocrine tumors (NETs), with low risk of toxicity. "
02/01/2015 - "Peptide receptor radionuclide therapy (PRRT) is a promising treatment for patients with neuroendocrine tumors, giving rise to improved survival. "
07/01/2014 - "Peptide receptor radionuclide therapy (PRRT) is a promising treatment option for patients with metastatic or unresectable pulmonary neuroendocrine tumors. "
11/01/2014 - "Standardization would help define the characteristics of response, including progression-free survival; provide homogeneous phase II and III studies; delineate the position of peptide receptor radionuclide therapy in the therapeutic algorithm for neuroendocrine tumors; and establish the basis for approval by the regulatory authorities. "
08/01/2015 - "Complete Remission of Metastatic Neuroendocrine Paragastric Carcinoma After "Neoadjuvant" Peptide Receptor Radionuclide Therapy and Surgery."
10/01/2013 - "First experience using peptide receptor radionuclide therapy in a patient with urothelial carcinoma."
02/01/2007 - "These studies revealed the presence of the 3 known natriuretic peptide receptors A, B and C in PC-3 and DU-145 human prostate carcinoma cells (American Type Culture Collection, Manassas, Virginia) as well as in tissue samples of human prostate cancer. "
12/01/2014 - "Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma/carcinoma: variable clinical response in preliminary evaluation."
04/01/1986 - "We have identified a factor constitutively produced by the human bladder carcinoma cell line 5637, which has the following capacities: to induce the differentiation of the human promyelocytic leukemic cell line HL-60; to induce the expression of chemotactic peptide receptors in leukemic cells as well as in normal peripheral blood granulocytes; to function as a chemoattractant for neutrophils as well as, under certain conditions, inhibiting their migration; to support the growth of eosinophil and granulocyte/macrophage progenitors, which is maximal when scored at day 14; and to support the growth of human mixed pluripotent progenitors and erythroid bursts from normal human bone marrow. "
|4.||Neoplasm Metastasis (Metastasis)
04/15/2015 - "Peptide receptor radionuclide therapy is a promising palliative procedure for patients with hepatic and/or extrahepatic metastases. "
01/01/2014 - "Can peptide receptor radionuclide therapy be safely applied in florid bone metastases? "
01/01/2013 - "Bone metastases (BM) of gastroenteropancreatic neuroendocrine tumours (GEP-NET) can be effectively controlled by peptide receptor radionuclide therapy (PRRT). "
10/01/2012 - "A patient with liver metastases from BC was treated with peptide receptor radionuclide therapy (PRRT). "
02/01/2012 - "Peptide receptor radionuclide therapy (PRRT) consists in the systemic administration of a synthetic peptide, labelled with a suitable beta-emitting radionuclide, able to irradiate tumours and their metastases via the internalization through a specific receptor, overexpressed on the cell membrane. "
|5.||Cardiomegaly (Heart Hypertrophy)
04/01/2002 - "Progressive cardiac hypertrophy and dysfunction in atrial natriuretic peptide receptor (GC-A) deficient mice."
05/31/2011 - "Caveolae, microdomains in the plasma membrane that contain caveolin proteins and natriuretic peptide receptors, have been implicated in cardiac hypertrophy and natriuretic peptide localization. "
05/06/2008 - "Mice lacking guanylyl cyclase-A (GC-A), a natriuretic peptide receptor, have pressure-independent cardiac hypertrophy. "
05/01/2003 - "Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A."
01/01/2000 - "Atrial natriuretic peptide (ANP) may function as an endogenous regulator of cardiac hypertrophy, because the natriuretic peptide receptor has been found in the heart and because mice lacking its receptor have been shown to have a markedly elevated ventricular mass. "
|1.||Somatostatin (Somatotropin Release-Inhibiting Factor)
|2.||Somatostatin Receptors (Somatostatin Receptor)
|4.||Guanylate Cyclase (Guanylyl Cyclase)
|5.||Vasoactive Intestinal Peptide (VIP (Vasoactive Intestinal Peptide))
|1.||Drug Therapy (Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)